Wegovy® (Semaglutide 2.4mg) — Once-Weekly GLP-1 Therapy for Chronic Weight Management

First GLP-1 Receptor Agonist Approved for Long-Term Weight Management

Wegovy® (Semaglutide 2.4mg) is a once-weekly glucagon-like peptide-1 (GLP-1) receptor agonist approved for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity. It is the highest approved dose of Semaglutide and represents a significant advance in the pharmacological treatment of obesity.

A.K. Pharma is a trusted medicine distributor in Delhi supplying genuine Wegovy (Semaglutide 2.4mg) to hospitals, obesity clinics, endocrinology centres, and pharmacies across India. Manufactured by Novo Nordisk, a global leader in metabolic disease treatment, Wegovy has transformed the approach to obesity management globally.

---

What is Wegovy (Semaglutide 2.4mg)?

Wegovy contains Semaglutide at a dose of 2.4mg — higher than the diabetes formulation Ozempic (maximum 2mg). At this higher dose, Semaglutide’s appetite-suppressing effects are maximised, leading to significantly greater weight loss than lower doses.

Semaglutide acts on GLP-1 receptors in the brain’s appetite-regulating centres, reducing hunger signals and food cravings. It also slows gastric emptying, prolonging feelings of fullness after meals. These combined central and peripheral effects result in substantial and sustained weight reduction.

Full prescribing information is available at the FDA label for Wegovy.

---

Clinical Studies and Evidence

STEP 1 Trial (Semaglutide for Obesity without Diabetes) Published in the New England Journal of Medicine (2021), the STEP 1 trial demonstrated that Semaglutide 2.4mg achieved a mean weight reduction of 14.9% from baseline compared to 2.4% with placebo in adults with obesity or overweight without diabetes over 68 weeks.

STEP 2 Trial (Semaglutide for Obesity with Type 2 Diabetes) Published in the Lancet (2021), the STEP 2 trial showed Semaglutide 2.4mg achieved a mean weight reduction of 9.6% compared to 3.4% with placebo in adults with Type 2 diabetes and obesity.

STEP 3 Trial (Semaglutide with Intensive Behavioural Therapy) The STEP 3 trial demonstrated that Semaglutide 2.4mg plus intensive behavioural therapy achieved a mean weight reduction of 16% compared to 5.7% with placebo plus intensive behavioural therapy.

STEP 4 Trial (Sustained Weight Loss) The STEP 4 trial showed that patients who continued Semaglutide 2.4mg after 20 weeks maintained and continued to lose weight, while those who switched to placebo regained approximately two-thirds of their lost weight, demonstrating the importance of continued therapy.

SELECT Trial (Cardiovascular Outcomes in Obesity) Published in the New England Journal of Medicine (2023), the SELECT trial demonstrated that Semaglutide 2.4mg reduced the risk of major adverse cardiovascular events by 20% in adults with obesity and established cardiovascular disease without diabetes — the first weight loss medicine to demonstrate cardiovascular benefit.

---

Available Strengths and Dose Escalation

Wegovy follows a structured dose escalation schedule:

This gradual escalation minimises gastrointestinal side effects. If the 2.4mg maintenance dose is not tolerated, a dose reduction to 1.7mg is permitted.

---

Indications — What Wegovy is Used For

Wegovy is approved as an adjunct to a reduced-calorie diet and increased physical activity for:

• Chronic weight management in adults with initial BMI ≥30 kg/m² (obesity)
• Chronic weight management in adults with initial BMI ≥27 kg/m² (overweight) with at least one weight-related comorbidity such as hypertension, Type 2 diabetes, or dyslipidaemia
• Reduction of risk of serious cardiovascular events in adults with obesity or overweight and established cardiovascular disease (SELECT trial indication)

Note: Wegovy is not a substitute for Ozempic in diabetes management and should not be used in combination with other Semaglutide products.

For detailed indication information refer to MedlinePlus Semaglutide Injection for Weight Management.

---

Key Benefits of Wegovy

Clinically Significant Weight Loss Wegovy achieves average weight loss of 15-20% of body weight — the most significant weight reduction of any approved non-surgical weight management treatment, approaching results seen with bariatric surgery in some patients.

Sustained Weight Reduction Unlike many weight loss treatments, Wegovy produces sustained weight loss over the treatment period as demonstrated across the STEP trials programme.

Cardiovascular Protection The SELECT trial demonstrated a 20% reduction in cardiovascular events with Wegovy in patients with obesity and cardiovascular disease — the first weight management medicine with proven cardiovascular benefit.

Improvement in Comorbidities Beyond weight loss, Wegovy improves obesity-related comorbidities including blood pressure, blood sugar, cholesterol levels, and markers of inflammation.

Convenient Once-Weekly Dosing A single weekly injection improves patient adherence and convenience compared to daily medications.

Well-Established Safety Profile Semaglutide has an extensive safety database from both the SUSTAIN (diabetes) and STEP (obesity) clinical trial programmes involving thousands of patients.

---

How Wegovy Works

Wegovy works through multiple complementary mechanisms:

• Central appetite suppression — acts on GLP-1 receptors in the hypothalamus and brainstem to reduce hunger signals and food cravings
• Slows gastric emptying — food stays in the stomach longer, prolonging satiety after meals
• Reduces caloric intake — patients naturally eat less due to reduced appetite and earlier satiety
• Improves insulin sensitivity — particularly beneficial in patients with prediabetes or Type 2 diabetes
• Cardiovascular effects — direct cardioprotective effects on the heart and blood vessels beyond weight reduction alone

For a detailed mechanism overview refer to the American Society for Metabolic and Bariatric Surgery guidelines.

---

Wegovy vs Mounjaro — Weight Management Comparison

---

Dosage and Administration

• Route: Subcutaneous injection once weekly
• Injection Sites: Abdomen, thigh, or upper arm — rotate sites with each injection
• Timing: Same day each week, with or without food, at any time of day
• Dose Escalation: Follow structured 16-week escalation schedule to 2.4mg maintenance dose
• Missed Dose: Administer within 5 days of missed dose — if more than 5 days have passed, skip and resume on next scheduled day

Full dosing guidelines available at Drugs.com Wegovy Dosage.

---

Who Should Use Wegovy

Wegovy is prescribed for:

• Adults with BMI ≥30 kg/m² (obesity) requiring long-term weight management
• Adults with BMI ≥27 kg/m² (overweight) with at least one weight-related comorbidity
• Adults with obesity and established cardiovascular disease requiring cardiovascular risk reduction
• Patients who have not achieved adequate weight loss with lifestyle interventions alone

Wegovy is prescribed by endocrinologists, bariatric physicians, diabetologists, cardiologists, and general physicians. A.K. Pharma supplies Wegovy to hospitals, obesity clinics, and pharmacies across Delhi and India.

---

Possible Side Effects

Common side effects include nausea, vomiting, diarrhoea, constipation, abdominal pain, and headache. These are most common during dose escalation and typically improve over time.

Serious side effects include:

• Pancreatitis — discontinue immediately if suspected
• Acute gallbladder disease including cholelithiasis
• Hypoglycaemia — risk increases if used with insulin or sulfonylureas in diabetic patients
• Acute kidney injury — monitor in patients with renal impairment
• Diabetic retinopathy complications
• Suicidal ideation and behaviour — monitor for depression or mood changes
• Allergic reactions including anaphylaxis

Full side effect information available at FDA Wegovy Safety Information.

---

Precautions

• Do not use in patients with personal or family history of medullary thyroid carcinoma (MTC) or MEN 2
• Not indicated for Type 1 diabetes
• Do not use in combination with other Semaglutide products (Ozempic, Rybelsus) or other GLP-1 receptor agonists
• Do not use in combination with Mounjaro or other GIP/GLP-1 receptor agonists
• Discontinue at least 2 months before planned pregnancy
• Not recommended during pregnancy or breastfeeding
• Monitor for depression, suicidal ideation, or mood changes during treatment
• Refer to WHO Obesity Fact Sheet for broader obesity management context

---

Storage and Handling

• Store unused pens in refrigerator between 2°C and 8°C
• Do not freeze — discard if frozen
• Once in use, pen can be stored at room temperature below 30°C for up to 56 days
• Keep away from direct sunlight and heat
• Store with cap on and needle removed

A.K. Pharma maintains full cold chain requirements during storage and supply of Wegovy, ensuring product integrity for every unit supplied to hospitals and pharmacies across India.

---

Manufacturer Information

Wegovy (Semaglutide 2.4mg) is manufactured by Novo Nordisk A/S, a global leader in metabolic diseases with over 100 years of experience in diabetes and obesity care. Wegovy received FDA approval in June 2021 for chronic weight management. A.K. Pharma supplies only genuine Wegovy sourced from authorized distributors.

---

Related Obesity and Diabetes Medicines Available at A.K. Pharma

• Ozempic (Semaglutide) — lower dose Semaglutide for Type 2 diabetes management
• Mounjaro (Tirzepatide) — dual GLP-1/GIP receptor agonist with greater weight loss
• Browse all Obesity Medicines available at A.K. Pharma
• Browse all Diabetes Medicines available at A.K. Pharma

---

Frequently Asked Questions

Q. What is Wegovy used for? Wegovy (Semaglutide 2.4mg) is approved for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity, as an adjunct to diet and exercise. More information available at MedlinePlus.

Q. What is the difference between Wegovy and Ozempic? Both contain Semaglutide but at different doses and for different indications. Ozempic (0.5mg-2mg) is approved for Type 2 diabetes management. Wegovy (2.4mg) is approved specifically for chronic weight management. Wegovy achieves greater weight loss due to its higher dose.

Q. How much weight can I expect to lose with Wegovy? Clinical trials show an average weight loss of 14.9% to 16% of body weight with Wegovy over 68 weeks when combined with diet and exercise. Individual results vary based on starting weight, diet, and physical activity.

Q. Is Wegovy available in India? Wegovy can be supplied to hospitals, obesity clinics, and pharmacies across India through licensed pharmaceutical distributors. Contact A.K. Pharma — medicine distributor in Delhi — for availability and pricing.

Q. What is the price of Wegovy in India? Wegovy price in India varies by strength and pack size. Contact A.K. Pharma at 011 4172 6999 or WhatsApp +91 9810034827 for current pricing and bulk supply rates.

Q. How to order Wegovy from A.K. Pharma? You can request a quote directly from this page, call us at 011 4172 6999, or WhatsApp us at +91 9810034827 with your requirements and we will respond promptly.

Q. Does A.K. Pharma supply Wegovy in bulk? Yes. A.K. Pharma supplies Wegovy in bulk to hospitals, obesity clinics, endocrinology centres, and pharmacies across Delhi and India. Contact us for bulk pricing and availability.

Q. Where can I find clinical evidence for Wegovy? Key Wegovy clinical trials including STEP 1, STEP 2 and SELECT are published in the New England Journal of Medicine and The Lancet. FDA approval information is available at FDA.gov.

---

Why Order Wegovy from A.K. Pharma?

• Licensed medicine distributor in Delhi with all required drug licenses
• 100% genuine Wegovy sourced from authorized Novo Nordisk distributors
• Cold chain maintained throughout storage and delivery
• Bulk supply available for hospitals, clinics, and pharmacies
• Prompt response to all quote requests
• Serving endocrinologists and bariatric physicians across Delhi NCR and India

---

Contact A.K. Pharma for Wegovy Supply 📍 E-2/257A, 2nd Floor, Shastri Nagar, New Delhi 110052 📞 011 4172 6999 📱 WhatsApp: +91 9810034827 🌐 akpharma.in